Centro De Ingenieria Genetica Y Biotecnologia

Other

Hilda Elisa Garay Perez

Osvaldo Reyes Acosta

Gerardo Enrique Guillen Nieto

Jesús Arturo Junco Barranco

Eulogio Pimentel Vazquez

Ania Cabrales Rico

Yunier Rodriguez Alvarez

Niurka Oneysi Arteaga More

Maria Castro Santana

Lesvia Calzada Aguilera

Yovisleidys Lopez Saez

Roberto Basulto Baker

Franklin Fuentes Aguilar

Eddy Emilio Bover Fuentes

Luis Alberto Aguero Barrocal

Glay Chinea Santiago

Alexis Musacchio Lasa

Boris Ernesto Acevedo Castro

Osmany Guirola Cruz

Maribel Guerra Vallespi

Alicia Santos Savio

Vivian Huerta Galindo

Haydee Geronimo Perez

Noralvis Fleitas Salazar

Raimundo Ubieta Gomez

Alejandro Miguel Martin Dunn

Patricia Gabriela Toledo Mayora

Gabriel Ramon Padron Palomares

Eduardo Martinez Diaz

Ernesto Lopez Mola

Vladimir Armando Besada Perez

Maritza Pupo Antunez

Rosmari Rodriguez Roche

Gabriel Padron Palomares

Luis Morier Diaz

Luis Javier Gonzalez Lopez

Maylin Alvarez Vera

Omaida Perez Insuita

Jose Luis Pelegrino Martinez De La Cotera

Ana Beatriz Perez Diaz

Cruz Matilde Lopez Abad

Gerardo Enríque Guillen Nieto

Monica Sarria Nunez

Aniel Sanchez Puente

Orlando Luis Pardo Lazo

Guadalupe Guzman Tirado

Susana Vazquez Ramudo

Alexis Yero Diaz

Gabriel Jesus Marquez Perera

Karen Alvarez Perez

Rocio Garateix Suarez

Dianne Pupo Gomez

María Castro Santana

Gerardo Enrique GUILLÉN Nieto

Sonia Gonzalez Blanco

Maria Del Abrahantes Perez

Isis Del Torrens Madrazo

Jesus Arturo Junco Barranco

The present invention discloses an antagonist peptide of the Interleukin-15 (IL-15) activity, which is characterized in that it comprises an amino acid sequence identified as SEQ ID No. 5 or SEQ ID No. 12, or a homodimer of these peptides, as well as a nucleic acid that encodes for the peptide with the sequence identified as SEQ ID No. 5 or SEQ ID No. 12. Pharmaceutical compositions comprising said peptides or nucleic acids encoding said sequences are part of the invention. In addition, it provides the use of an IL-15 antagonist peptide comprising the amino acid sequence identified as SEQ ID No. 5 or SEQ ID No. 12, or a homodimer of these peptides, for the manufacture of a medicament. The invention contemplates a method for the treatment of a disease related to the IL-15 overexpression, prostate and kidney cancer.

Interleukin-15 activity antagonist peptide

A pharmaceutical composition using natural gonadotropin&#x2014;releasing hormone (GnRH), and/or some of its mimetic peptides, indistinctly bound by its amino or carboxyl extremes to a carrier molecule; in one case by its carboxyl extreme and in the other case by the amino terminal extreme, thus eliciting a faster and more potent immunological response against the endogenous GnRH hormone. This finally leads to the ablation of the GnRH and consequently of the rest of the involved hormones in the stream GnRH/LH-FSH/Testosterone-(estrogens). An advantage of this formulation consists on facilitating the exposition to the immune system of a greater number of epitopes of the GnRH or its mimetics, minimizing thus the steric hindrance produced by the carriers. This invention has a direct application in the castration of pets and animals of economic interest, in the control of human fertility as well as in the treatment of hormone-sensitive tumors, such as that of the prostate, the breast, ovary, the endometry, testicles, hypophysis, salivary glands and other kinds of human tumors.

Pharmaceutical composition using gonadotropin-releasing hormone (GNRH) combined variants as immunogen

A pharmaceutical composition using natural gonadotropin-releasing hormone (GnRH), and/or some of its mimetic peptides, indistinctly bound by its amino or carboxyl extremes to a carrier molecule; in one case by its carboxyl extreme and in the other case by the amino terminal extreme, thus eliciting a faster and more potent immunological response against the endogenous GnRH hormone. This finally leads to the ablation of the GnRH and consequently of the rest of the involved hormones in the stream GnRH/LH-FSH/Testosterone-(estrogens). An advantage of this formulation consists on facilitating the exposition to the immune system of a greater number of epitopes of the GnRH or its mimetics, minimizing thus the steric hindrance produced by the carriers. This invention has a direct application in the castration of pets and animals of economic interest, in the control of human fertility as well as in the treatment of hormone-sensitive tumors, such as that of the prostate, the breast, ovary, the endometry, testicles, hypophysis, salivary glands and other kinds of human tumors.

The present invention is related to the field of molecular immunology, particularly to a peptide derived from the sequence of interleukine-15 (IL-15), wherein said peptide was optimized to inhibit the biological activity of this molecule. In the present invention, it is shown that this peptide inhibits IL-15-induced T cell proliferation, Tumor Necrosis Factor &#x3b1; (TNF&#x3b1;) induction and the expression of IL-8 and IL-6 by the IL-15 receptor &#x3b1; subunit (IL-15R&#x3b1;), all these effects mediated by the binding of the peptide to the IL-15R&#x3b1;. The invention is also related to the use of the peptide to treat pathologies where the abnormal expression of IL-15 or IL-15R&#x3b1; is related to the course of the disease, such as rheumatoid arthritis (RA) and prostate cancer.

Peptide antagonist of interleukin-15 activity

The present invention is related to a method for blocking the infection of cells by dengue virus, based on interfering the direct interaction of the viral envelope protein with a cellular receptor or its indirect interaction with said cellular receptor through a carrier protein, as well as related uses; wherein said cellular receptor is the alpha-2 macroglobulin receptor, also known as the low density receptor-related protein or as CD91, and said carrier protein is human alpha-2 macroglobulin.

Method to block the infection by flaviviruses, molecules and uses

The present invention relates to five synthetic peptides of pre-M/M protein of Dengue-2 virus, corresponding to amino acid sequences 3-31, 45-67, 57-92, 69-93 and 103-124. The anti-peptide immune response was evaluated in mice. Recombinant fusion proteins were also obtained, including regions of pre-M/M protein. The presence of B cell epitopes in both mice and humans was demonstrated in the pre-M/M protein peptides. Peptides 3-31 and 103-124 elicited neutralizing antibodies against the four serotypes of Dengue virus. Virus-specific proliferative responses were demonstrated in mice immunized with non-conjugated peptides 3-31 and 57-92. Mice immunized with conjugated peptides 3-31, 57-92, and 69-93 were protected when they were challenged with Dengue-2 virus. Thus, the presence of sequential epitopes in Pre-M/M protein of Dengue-2 virus was demonstrated, as well as their relevance in the immune response against this flavivirus.

Pre-M/M epitopes of dengue virus, synthetic peptides, chimeric proteins and their use

Growing community of inventors

Ciudad Habana, Cuba

Hilda Elisa Garay Perez